



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/23626/2020

European Medicines Agency decision P/0048/2020

of 29 January 2020

on the agreement of a paediatric investigation plan for factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIIIFc-VWF-XTEN) (EMEA-002501-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0048/2020

of 29 January 2020

on the agreement of a paediatric investigation plan for factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIII-Fc-VWF-XTEN) (EMA-002501-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bioverativ Therapeutics, Inc., a Sanofi Company on 19 December 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 December 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIIIIFc-VWF-XTEN), powder and solvent for solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Bioverativ Therapeutics, Inc., a Sanofi Company, 225 Second Avenue, 02451 - Waltham, MA, USA.

EMA/PDCO/541299/2019
Amsterdam, 11 December 2019

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMA-002501-PIP01-18

Scope of the application

Active substance(s):

Factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIIIIFc-VWF-XTEN)

Condition(s):

Treatment of congenital haemophilia A

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Bioverativ Therapeutics, Inc., a Sanofi Company

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bioverativ Therapeutics, Inc., a Sanofi Company submitted for agreement to the European Medicines Agency on 19 December 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 29 January 2019.

Supplementary information was provided by the applicant on 6 September 2019. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a deferral.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of congenital haemophilia A.

2.1.1. Indication(s) targeted by the PIP

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 1 (242HA301) Open-label study to evaluate pharmacokinetics, safety and efficacy of rFVIIIFc-VWF-XTEN in adolescents from 12 to less than 18 years of age (and adults) with severe haemophilia A. Study 2 (242HA302) Open-label study to evaluate pharmacokinetics, safety and efficacy of rFVIIIFc-VWF-XTEN administered as prophylaxis in previously treated patients (PTPs) from birth to less than 12 years of age with severe haemophilia A.
Extrapolation, modelling and simulation studies	0	Not applicable.

Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	No